SENSEI BIOTHERAPEUTICS INC. - COMMON STOCK

Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights

09 May 2024 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting

24 Apr 2024 16:05:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Participate in Canaccord Genuity’s Horizons in Oncology Virtual Conference

09 Apr 2024 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment

04 Apr 2024 16:05:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium

22 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences

06 Mar 2024 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights

28 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Present at Upcoming Conferences

07 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones

04 Jan 2024 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

07 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Reports Favorable Clinical Data for SNS-101 at 2023 SITC Annual Meeting

03 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Appoints Stephanie Krebs, MS, MBA, as Chief Business Officer

01 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Present Initial Clinical Data from Dose Escalation Trial of SNS-101 at 2023 SITC Annual Meeting

25 Oct 2023 09:05:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Presents Trial-in-Progress Poster for Phase 1/2 Clinical Study of SNS-101 at ESMO 2023

23 Oct 2023 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Announces Initiation of Combination Arm for Phase 1/2 Clinical Study of SNS-101 with Regeneron’s Libtayo®

27 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Presents New Preclinical Data Reinforcing SNS-101 Pharmacokinetic Profile, Safety Characteristics and Mechanism of Action at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

21 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Present New Preclinical Data Supporting Mechanism of Action, Pharmacokinetic Profile and Safety Characteristics for SNS-101, a Conditionally Active VISTA-blocking Antibody, at the Seventh CRI-ENCI-AACR International Cancer Immunotherapy Conference

13 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Participate in Upcoming Investor Conferences

30 Aug 2023 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights

03 Aug 2023 07:30:00 By Nasdaq GlobeNewswire

Sensei Biotherapeutics to Participate in Canaccord Genuity’s 43rd Annual Growth Conference

02 Aug 2023 07:30:00 By Nasdaq GlobeNewswire